Klothea Bio has secured funding from Longevitytech.fund to pioneer breakthrough treatments for metabolic syndrome and several age-related diseases.
Advantage Therapeutics, which develops therapies targeting age-related diseases, has announced the formation of its new subsidiary, Klothea Bio, which will focus exclusively on the research and development of klotho-based therapies to prevent and treat various age-associated conditions.
The new subsidiary is backed by seed funding led by Longevitytech.fund (LTF) that invests in biotechnology startups focused on healthy lifespan extension globally.
Klothea Bio, will build upon Advantage Therapeutics’ proprietary IP portfolio centred around klotho, a protein renowned for its significant anti-ageing properties, including neuroprotection, antioxidative effects, and tumour suppression.
Klotho levels decrease with age to dangerous levels. Initial studies will target metabolic disease syndrome, with subsequent research aimed at expanding therapeutic applications to cancer, Alzheimer’s disease, obesity, and other age-related indications.
Jeffrey Madden, chairman of Klothea Bio, said: “As we embark on this exciting journey, we expect to demonstrate that our mRNA therapy will increase significantly the levels of Klotho to those found in young and healthy individuals and will offer the potential for longer-lasting therapeutic effects which may delay or prevent certain age-related diseases.
“We are thrilled to partner with Longevitytech.fund as our lead investor, advancing our mission to realize the transformative potential of Klotho protein therapies for aging-related diseases.
“This collaboration strengthens Klothea Bio’s laser focus on developing safe and effective treatments as we prepare for our upcoming clinical trial, bringing us closer to a future where significantly extending healthy human lifespan is achievable.”
Petr Sramek, Managing Partner of Longevitytech.fund and Klothea Board Member, expressed enthusiasm for supporting Klothea Bio’s mission. “Longevitytech.fund is committed to advancing solutions that address the hallmarks of aging, and we see Klotho as a critical protein in a molecular pathway to enhance human health and longevity. By supporting Klothea Bio, we aim to enable pioneering science that holds the promise of reducing the burden of age-associated diseases.”
Dr. Carmela Abraham, Advantage’s CSO, added: “Klotho is a protein possessing multiple beneficial and unique pleotropic functions by protecting organs against inflammation, oxidative stress, tumour growth, while its absence leads to age-related diseases and early death.”
